PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Sciences, Clinical Development and Medical Affairs, Biocon Biologics India Ltd , Bengaluru, India.\', \'Consultant, Joshi Clinic and Lilavati Hospital , Mumbai, India.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/14712598.2020.1798399
?:hasPublicationType
?:journal
  • Expert opinion on biological therapy
is ?:pmid of
?:pmid
?:pmid
  • 32700604
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.117
?:rankingScore_hIndex
  • 73
is ?:relation_isRelatedTo_publication of
?:title
  • Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32700604>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32700604>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all